These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27511992)

  • 1. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.
    Arihiro K; Oda M; Ohara M; Kadoya T; Osaki A; Nishisaka T; Shiroma N; Kobayashi Y
    Jpn J Clin Oncol; 2016 Dec; 46(12):1081-1087. PubMed ID: 27511992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
    Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
    Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
    Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
    J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment.
    Kwon AY; Park HY; Hyeon J; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Cho SY; Cho EY
    PLoS One; 2019; 14(2):e0212309. PubMed ID: 30785924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
    Thangarajah F; Enninga I; Malter W; Hamacher S; Markiefka B; Richters L; Krämer S; Mallmann P; Kirn V
    Anticancer Res; 2017 Apr; 37(4):1957-1964. PubMed ID: 28373466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.
    Varga Z; Li Q; Jochum W; Perriard U; Rau T; Tille JC; Hawle H; Klingbiel D; Thuerlimann B; Ruhstaller T
    Sci Rep; 2019 Sep; 9(1):13534. PubMed ID: 31537812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.
    Ono M; Tsuda H; Yunokawa M; Yonemori K; Shimizu C; Tamura K; Kinoshita T; Fujiwara Y
    Breast Cancer; 2015 Mar; 22(2):141-52. PubMed ID: 23584595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature.
    Liu Y; Yin W; Yan T; Du Y; Shao Z; Lu J
    Curr Med Res Opin; 2013 Nov; 29(11):1453-61. PubMed ID: 23927551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of the free web-based image analysis application ImmunoRatio for assessment of Ki-67 labelling index in breast cancer.
    Yeo MK; Kim HE; Kim SH; Chae BJ; Song BJ; Lee A
    J Clin Pathol; 2017 Aug; 70(8):715-719. PubMed ID: 28298390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
    Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
    Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients.
    Tamaki K; Ishida T; Tamaki N; Kamada Y; Uehara K; Miyashita M; Amari M; Tadano-Sato A; Takahashi Y; Watanabe M; McNamara K; Ohuchi N; Sasano H
    Breast Cancer; 2014 May; 21(3):325-33. PubMed ID: 22782361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.